| Literature DB >> 31725732 |
James J Zhu1, Palaniappan Ramanathan2, Elizabeth A Bishop1, Vivian O'Donnell3, Douglas P Gladue1, Manuel V Borca1.
Abstract
African swine fever (ASF) is a swine disease caused by a large, structurally complex, double-stranded DNA virus, African swine fever virus (ASFV). In domestic pigs, acute infection by highly virulent ASF viruses causes hemorrhagic fever and death. Previous work has suggested that ASFV pathogenesis is primarily mediated by host cytokines produced by infected monocytes and macrophages. To better understand molecular mechanisms mediating virus pathogenesis and immune evasion, we used transcriptome analysis to identify gene expression changes after ASFV infection in ex vivo swine macrophages. Our results suggest that the cytokines of TNF family including FASLG, LTA, LTB, TNF, TNFSF4, TNFSF10, TNFSF13B and TNFSF18 are the major causative cytokine factors in ASF pathogenesis via inducing apoptosis. Other up-regulated proinflammatory cytokines (IL17F and interferons) and down-regulated anti-inflammatory cytokine (IL10) may also significantly contribute to ASF pathogenesis and cause excessive tissue inflammatory responses. The differential expression of genes also indicates that ASFV could evade both the innate and adaptive immune responses by (i) inhibiting MHC Class II antigen processing and presentation, (ii) avoiding CD8+ T effector cells and neutrophil extracellular traps via decreasing expression of neutrophil/CD8+ T effector cell-recruiting chemokines, (iii) suppressing M1 activation of macrophages, (iv) inducing immune suppressive cytokines, and (v) inhibiting the processes of macrophage autophagy and apoptosis. These results provide novel information to further investigate and better understand the mechanism of pathogenesis and immune evasion of this devastating swine disease.Entities:
Year: 2019 PMID: 31725732 PMCID: PMC6855437 DOI: 10.1371/journal.pone.0223955
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The numbers and percentages of microarray probes with significant (false discovery rate < 0.05) differential expression and significant differences by at least 50% between infected and non-infected macrophages, respectively, during the first 18 hours of ASFV infection.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr |
|---|---|---|---|---|---|---|
| Significantly up-regulated | 1 | 2267 | 628 | 1732 | 1423 | 3315 |
| Significantly down-regulated | 1 | 1193 | 528 | 3075 | 2323 | 5253 |
| Up-regulated by ≥ 50% | 1 | 28% | 59% | 36% | 51% | 48% |
| Down-regulated by ≥ 50% | 1 | 15% | 11% | 27% | 49% | 51% |
Fig 1The number of significant (false discovery rate ≤0.05) differentially expressed gene (DEG) probes with a difference of 50% or great during the first 18 hours of infection.
Immune-related biological pathways with over-represented genes of 1481 significantly up-regulated genes using a web tool (DAVID Bioinformatics Resources 6.8) during the first 18 hours of infection.
| Pathway # | Biological pathways | Hours PI | Count | FDR |
|---|---|---|---|---|
| GO:0006915 | apoptotic process | 6 | 30 | 0.03 |
| GO:0045824 | negative regulation of innate immune response | 6 | 6 | 0.00 |
| GO:0045071 | negative regulation of viral genome replication | 6, 9, 12, 15 | 16 | 0.00 |
| GO:0060333 | interferon-gamma-mediated signaling pathway | 6, 9, 12, 15 | 18 | 0.00 |
| GO:0006955 | immune response | 6, 9, 12, 15, 18 | 27 | 0.00 |
| GO:0009615 | response to virus | 6, 9, 12, 15, 18 | 22 | 0.00 |
| GO:0032480 | negative regulation of type I interferon production | 6, 9, 12, 15, 18 | 11 | 0.00 |
| GO:0045087 | innate immune response | 6, 9, 12, 15, 18 | 32 | 0.00 |
| GO:0051607 | defense response to virus | 6, 9, 12, 15, 18 | 38 | 0.00 |
| GO:0060337 | type I interferon signaling pathway | 6, 9, 12, 15, 18 | 25 | 0.00 |
| R-HSA-877300 | Interferon gamma signaling | 6, 9, 12, 15, 18 | 21 | 0.00 |
| R-HSA-909733 | Interferon alpha/beta signaling | 6, 9, 12, 15, 18 | 25 | 0.00 |
| R-HSA-936440 | Negative regulators of DDX58/IFIH1 signaling | 6, 9, 12, 15, 18 | 10 | 0.00 |
| GO:0006954 | inflammatory response | 6, 12, 18 | 27 | 0.00 |
| GO:0032689 | negative regulation of interferon-gamma production | 9 | 6 | 0.04 |
| GO:0032728 | positive regulation of interferon-beta production | 12 | 7 | 0.04 |
| hsa04620 | Toll-like receptor signaling pathway | 12 | 13 | 0.02 |
| hsa04622 | RIG-I-like receptor signaling pathway | 12 | 13 | 0.00 |
| hsa04623 | Cytosolic DNA-sensing pathway | 12 | 12 | 0.00 |
| R-HSA-918233 | TRAF3-dependent IRF activation pathway | 12 | 6 | 0.02 |
| R-HSA-933541 | TRAF6 mediated IRF7 activation | 12 | 8 | 0.02 |
| GO:0007165 | signal transduction | 12, 15, 18 | 52 | 0.00 |
| hsa04064 | NF-kappa B signaling pathway | 12, 15, 18 | 12 | 0.02 |
| GO:0002250 | adaptive immune response | 12, 18 | 16 | 0.00 |
| hsa04060 | Cytokine-cytokine receptor interaction | 12, 18 | 23 | 0.00 |
| R-HSA-380108 | Chemokine receptors bind chemokines | 12, 18 | 10 | 0.02 |
| GO:0031295 | T cell co-stimulation | 15 | 12 | 0.02 |
| GO:0050690 | regulation of defense response to virus by virus | 15 | 8 | 0.02 |
| GO:0050852 | T cell receptor signaling pathway | 15 | 18 | 0.00 |
| GO:0007166 | cell surface receptor signaling pathway | 15, 18 | 24 | 0.01 |
| hsa04660 | T cell receptor signaling pathway | 15, 18 | 16 | 0.00 |
| GO:0000184 | nonsense-mediated nuclear-transcribed mRNA decay | 18 | 23 | 0.00 |
| GO:0006614 | SRP-dependent co-translational protein targeting to membrane | 18 | 20 | 0.01 |
| GO:0006968 | cellular defense response | 18 | 15 | 0.03 |
| GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 18 | 23 | 0.00 |
| GO:0019083 | viral transcription | 18 | 21 | 0.02 |
| GO:0042110 | T cell activation | 18 | 15 | 0.00 |
| GO:0070098 | chemokine-mediated signaling pathway | 18 | 17 | 0.01 |
| GO:0072678 | T cell migration | 18 | 6 | 0.03 |
| hsa04062 | Chemokine signaling pathway | 18 | 32 | 0.01 |
| R-HSA-192823 | Viral mRNA Translation | 18 | 21 | 0.00 |
| GO:0033209 | tumor necrosis factor-mediated signaling pathway | pooled | 24 | 0.05 |
| hsa04650 | Natural killer cell mediated cytotoxicity | pooled | 28 | 0.01 |
| hsa05340 | Primary immunodeficiency | pooled | 13 | 0.02 |
: The number of differentially expressed genes in biological process or pathways.
: False discovery rate
: Differentially expressed genes were pooled from all tested time points
Differential expression (fold = infected/non-infected) with a FDR less than 0.05 at one or more time points and the averaged expression level (Exp) of cytokine genes between infected and non-infected macrophages at 3, 6, 9, 12, 15 and 18 hours post infection.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr | FDR | Exp |
|---|---|---|---|---|---|---|---|---|
| IL1A | 1.2 | 1.1 | 1.0 | -1.1 | 1.2 | 1.0 | 0.55 | 186 |
| IL1B_2 | 1.9 | 1.8 | 1.0 | -1.0 | 1.3 | 1.3 | 0.14 | 975 |
| IL1B_1 | 1.4 | 1.2 | 1.0 | 1.0 | 1.1 | -1.0 | 0.21 | 156 |
| IL1RN | 2.0 | 5.5 | 7.4 | 5.8 | 4.6 | 3.9 | 0.00 | 5986 |
| IL10 | -1.1 | 1.2 | -1.0 | -2.5 | -2.3 | -3.1 | 0.00 | 263 |
| IL13 | 1.1 | 1.3 | 1.0 | 1.7 | 2.1 | 2.3 | 0.02 | 45 |
| IL16 | -1.3 | -1.4 | -1.1 | -1.5 | -1.4 | -1.1 | 0.02 | 975 |
| IL17F | 1.1 | 1.0 | 1.2 | 1.7 | 2.9 | 3.5 | 0.04 | 218 |
| IL18BP | 1.2 | 1.3 | 1.4 | 1.8 | 1.9 | 2.3 | 0.00 | 1023 |
| IL27 | 1.8 | 2.8 | 1.8 | 1.6 | 1.4 | 1.3 | 0.01 | 398 |
| CSF3 | 1.6 | 1.7 | 1.1 | 1.1 | 1.4 | 1.4 | 0.04 | 452 |
| FASLG | 1.2 | 1.4 | 1.2 | 1.2 | 1.5 | 1.5 | 0.01 | 84 |
| LTA | -1.0 | 1.0 | 1.1 | 1.4 | 1.7 | 2.0 | 0.05 | 54 |
| LTB | 1.0 | -1.0 | 1.1 | 1.8 | 3.0 | 4.1 | 0.01 | 815 |
| TNF | 1.1 | 1.1 | 1.1 | 1.3 | 1.6 | 1.6 | 0.13 | 213 |
| TNFSF4 | 1.0 | 1.1 | 1.2 | 1.5 | 1.9 | 2.6 | 0.01 | 117 |
| TNFSF10 | 2.4 | 12.8 | 8.7 | 4.5 | 2.4 | 1.7 | 0.00 | 320 |
| TNFSF11 | -1.1 | -1.7 | -1.3 | -1.7 | -1.5 | -2.0 | 0.03 | 767 |
| TNFSF13B | 1.3 | 1.9 | 1.6 | 1.3 | 1.1 | -1.2 | 0.02 | 1119 |
| TNFSF15 | 1.0 | 1.2 | 1.1 | -1.0 | -1.5 | -1.9 | 0.00 | 397 |
| TNFSF18 | 1.5 | 2.2 | 2.1 | 1.7 | 1.3 | 1.1 | 0.01 | 126 |
| IFNA | 1.5 | 1.3 | 1.2 | 1.4 | 1.3 | 1.3 | 0.03 | 56 |
| IFNB | 3.1 | 1.0 | 1.5 | 3.0 | 3.5 | 3.6 | 0.02 | 79 |
| IFNL3 | 1.1 | 1.1 | 1.0 | 1.1 | 1.1 | 1.2 | 0.02 | 49 |
| IFNG | 1.1 | 1.4 | 1.3 | 1.3 | 1.9 | 2.1 | 0.01 | 153 |
* FDR: false discovery rate. Only the smallest FDR is listed for each gene.
Biological pathways with over-represented genes of 2340 significantly down-regulated genes using a web tool (DAVID Bioinformatics Resources 6.8) during the first 18 hours of infection.
| Pathway # | Pathway name | Hours PI | Count | FDR |
|---|---|---|---|---|
| GO:0016567 | protein ubiquitination | 15 | 39 | 0.04 |
| GO:0070125 | mitochondrial translational elongation | 15, 18 | 17 | 0.01 |
| R-HSA-5368286 | Mitochondrial translation initiation | 15, 18 | 16 | 0.01 |
| R-HSA-5389840 | Mitochondrial translation elongation | 15, 18 | 17 | 0.00 |
| R-HSA-5419276 | Mitochondrial translation termination | 15, 18 | 16 | 0.01 |
| GO:0002479 | antigen processing and presentation of via MHC class I, TAP-dependent | 18 | 21 | 0.03 |
| GO:0006122 | mitochondrial electron transport, ubiquinol to cytochrome c | 18 | 10 | 0.02 |
| GO:0006886 | intracellular protein transport | 18 | 57 | 0.00 |
| GO:0006888 | ER to Golgi vesicle-mediated transport | 18 | 39 | 0.02 |
| GO:0006914 | autophagy | 18 | 41 | 0.00 |
| GO:0015031 | protein transport | 18 | 89 | 0.00 |
| GO:0016236 | macroautophagy | 18 | 25 | 0.01 |
| GO:0019886 | antigen processing and presentation of via MHC class II | 18 | 27 | 0.02 |
| GO:0030433 | ER-associated ubiquitin-dependent protein catabolic process | 18 | 21 | 0.01 |
| GO:0033572 | transferrin transport | 18 | 17 | 0.00 |
| GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 18 | 45 | 0.05 |
| GO:0045454 | cell redox homeostasis | 18 | 24 | 0.02 |
| GO:0070126 | mitochondrial translational termination | 18 | 34 | 0.00 |
| GO:0090383 | phagosome acidification | 18 | 13 | 0.03 |
| hsa00190 | Oxidative phosphorylation | 18 | 46 | 0.00 |
| hsa01100 | Metabolic pathways | 18 | 220 | 0.00 |
| hsa04141 | Protein processing in endoplasmic reticulum | 18 | 52 | 0.00 |
| hsa04142 | Lysosome | 18 | 45 | 0.00 |
| hsa04145 | Phagosome | 18 | 51 | 0.00 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 18 | 48 | 0.00 |
| hsa05010 | Alzheimer’s disease | 18 | 51 | 0.00 |
| hsa05012 | Parkinson’s disease | 18 | 38 | 0.05 |
| R-HSA-1222556 | ROS, RNS production in phagocytes | 18 | 17 | 0.00 |
| R-HSA-1236974 | ER-Phagosome pathway | 18 | 27 | 0.01 |
| R-HSA-2132295 | MHC class II antigen presentation | 18 | 36 | 0.00 |
| R-HSA-5628897 | TP53 Regulates Metabolic Genes | 18 | 28 | 0.00 |
| R-HSA-5678895 | Defective CFTR causes cystic fibrosis | 18 | 21 | 0.03 |
| R-HSA-611105 | Respiratory electron transport | 18 | 30 | 0.00 |
| R-HSA-917977 | Transferrin endocytosis and recycling | 18 | 14 | 0.02 |
| GO:0006886 | intracellular protein transport | pooled | 62 | 0.00 |
| GO:0042147 | retrograde transport, endosome to Golgi | pooled | 23 | 0.03 |
| R-HSA-1268020 | Mitochondrial protein import | pooled | 20 | 0.05 |
| R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | pooled | 68 | 0.02 |
Differential expression (fold = infected/non-infected) with a FDR less than 0.05 at one or more time points and the averaged expression level (Exp) of chemokine genes between infected and non-infected macrophages at 3, 6, 9, 12, 15 and 18 hours post infection and their chemotactic activities.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr | FDR | Exp | Chemotactic |
|---|---|---|---|---|---|---|---|---|---|
| CCL2 | -1.0 | -1.1 | 1.0 | -1.7 | -3.2 | -5.1 | 0.01 | 42666 | Classical Mo,NK |
| CCL3 | 1.5 | 1.5 | -1.0 | 1.3 | 1.8 | 2.3 | 0.01 | 1686 | NC-Mo,NK |
| CCL4 | 2.3 | 2.9 | 1.7 | 3.1 | 4.1 | 5.2 | 0.01 | 2433 | NC-Mo,NK |
| CCL5 | 1.1 | 1.4 | 1.6 | 2.0 | 2.6 | 3.7 | 0.00 | 8536 | NC-Mo,NK |
| CCL8 | 1.7 | 1.8 | 1.1 | -1.4 | -1.8 | -2.6 | 0.01 | 10071 | Th2 |
| CCL14 | 1.0 | 1.1 | 1.0 | 1.3 | 1.5 | 1.8 | 0.01 | 199 | ? |
| CCL17 | 1.0 | 1.2 | 1.1 | 1.5 | 1.9 | 2.8 | 0.01 | 434 | Th2 |
| CCL20 | 2.4 | 2.3 | 1.4 | 1.2 | 1.2 | 1.1 | 0.00 | 232 | Th17 |
| CCL22 | 1.1 | 1.2 | 1.2 | 1.6 | 2.2 | 2.9 | 0.02 | 536 | Th2 |
| CXCL1 | 2.1 | 1.2 | -1.2 | -1.8 | -1.4 | -1.9 | 0.09 | 1089 | N,efCD8+,M,NK |
| CXCL2 | -1.1 | -1.2 | -1.2 | -1.3 | -1.2 | -1.3 | 0.04 | 77 | N,efCD8+,M,NK |
| CXCL3 | -1.4 | -2.0 | -1.4 | -2.6 | -2.5 | -3.6 | 0.01 | 1030 | N,efCD8+,M,NK |
| CXCL6 | 1.8 | 1.0 | -1.4 | -1.4 | -1.1 | -1.9 | 0.12 | 1806 | N,efCD8+,M,NK |
| CXCL8 | 1.5 | 1.0 | -1.1 | -1.4 | -1.0 | -1.2 | 0.36 | 1801 | N,efCD8+,M,NK |
| CXCL9 | 1.3 | 1.5 | 1.3 | 1.5 | 1.5 | 1.2 | 0.09 | 131 | CD8+,NK,Th1 |
| CXCL10 | 3.7 | 12.8 | 6.5 | 6.4 | 5.9 | 3.5 | 0.00 | 7991 | CD8+,NK,Th1 |
| CXCL11 | 1.4 | 3.1 | 2.6 | 2.5 | 3.3 | 3.7 | 0.00 | 78 | CD8+,NK,Th1 |
| CXCL14 | -1.3 | -1.4 | -1.1 | 1.0 | -1.5 | -1.9 | 0.03 | 1207 | B,DC,N,NK,M |
| CXCL16 | 1.1 | 1.2 | 1.4 | 1.5 | 1.3 | 1.2 | 0.00 | 4354 | CD8+,CD4+,NK |
| XCL1 | 1.2 | 1.6 | 1.7 | 2.0 | 2.5 | 3.2 | 0.01 | 177 | DC |
* The chemotactic activities are based on Griffith et al., 2014. CD8+ or CD4+: T cells; efCD8+: CD8+ effector T cell; DC: dendritic cell; N: neutrophil; NC: non-classical M: macrophage/monocyte; Mo: monocyte; NK: natural killer cells; and Th: T helper cell.
Differential expression (fold = infected/non-infected) with a FDR less than 0.05 at one or more time points and the averaged expression level (Exp) of cell receptor genes between infected and non-infected macrophages at 3, 6, 9, 12, 15 and 18 hours post infection.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr | FDR | Exp |
|---|---|---|---|---|---|---|---|---|
| IFNAR1 | -1.0 | -1.2 | -1.2 | -1.8 | -2.6 | -3.6 | 0.00 | 1173 |
| IFNAR2 | 1.0 | 1.0 | 1.1 | -1.2 | -1.6 | -2.0 | 0.01 | 2210 |
| IFNGR1 | -1.3 | -1.5 | -1.3 | -2.7 | -3.4 | -3.6 | 0.00 | 1073 |
| IL10RA | -1.2 | -1.1 | -1.0 | -2.3 | -3.0 | -2.9 | 0.00 | 544 |
| IL10RB | -1.0 | -1.0 | 1.0 | -1.1 | -1.3 | -1.6 | 0.01 | 1970 |
| IL17RA | -1.1 | -1.3 | 1.0 | -2.0 | -2.0 | -2.3 | 0.00 | 4191 |
| IL4R | -1.3 | -1.4 | -1.1 | -1.8 | -2.0 | -2.1 | 0.01 | 5753 |
| IL7R | 1.9 | 4.4 | 3.8 | 3.1 | 3.3 | 4.6 | 0.00 | 1853 |
| LTBR | -1.4 | -1.3 | -1.1 | -1.9 | -3.3 | -5.2 | 0.00 | 5487 |
| TNFRSF1A | -1.3 | -1.1 | -1.2 | -2.5 | -2.9 | -3.9 | 0.00 | 3846 |
| TNFRSF1B | -1.1 | -1.3 | 1.0 | -1.2 | -1.5 | -1.4 | 0.05 | 11675 |
| TNFRSF11A | 1.2 | 1.0 | -1.3 | -1.8 | -2.2 | -2.3 | 0.00 | 251 |
| TNFRSF25 | 1.1 | 1.1 | 1.2 | 1.6 | 1.8 | 2.2 | 0.02 | 129 |
| TNFRSF21 | 1.0 | -1.1 | 1.0 | -1.3 | -1.9 | -3.6 | 0.01 | 8369 |
| P2RX4 | 1.1 | -1.0 | -1.1 | -1.1 | -1.4 | -1.6 | 0.04 | 6386 |
| P2RX7 | -1.1 | -1.3 | -1.3 | -1.5 | -2.4 | -2.8 | 0.00 | 372 |
| P2RY1 | -1.7 | -2.1 | -1.4 | -2.5 | -3.4 | -3.6 | 0.00 | 695 |
| C3AR1 | 1.5 | 1.6 | 1.4 | -1.1 | -2.0 | -3.5 | 0.02 | 751 |
| C5AR1 | -1.2 | -1.4 | -1.2 | -2.5 | -4.8 | -7.5 | 0.00 | 13893 |
| CD1A | 1.1 | 1.0 | -1.7 | -1.5 | -1.7 | -1.7 | 0.00 | 749 |
| TLR1 | -1.2 | -1.4 | -1.1 | -1.9 | -2.4 | -2.8 | 0.00 | 200 |
| TLR2 | -1.3 | 1.0 | 1.1 | -2.2 | -3.9 | -5.7 | 0.00 | 10537 |
| TLR3 | 1.0 | 1.4 | 1.3 | 1.1 | -1.1 | -1.1 | 0.02 | 137 |
| TLR4 | -1.2 | -1.4 | -1.2 | -2.2 | -2.9 | -3.7 | 0.00 | 590 |
| TLR5 | 1.0 | -1.0 | 1.0 | -1.0 | 1.3 | 1.0 | 0.24 | 41 |
| TLR6 | -1.1 | -1.6 | -1.5 | -2.1 | -2.1 | -2.1 | 0.00 | 96 |
| TLR7 | 1.4 | 2.0 | 1.5 | -1.0 | -1.1 | -1.4 | 0.01 | 176 |
| TLR8 | 1.1 | 1.1 | 1.0 | -1.2 | -1.3 | -1.4 | 0.00 | 89 |
| TLR9 | -1.0 | -1.1 | -1.0 | -1.0 | -1.2 | -1.2 | 0.00 | 86 |
| TLR10 | -1.0 | -1.1 | -1.0 | -1.0 | -1.0 | -1.0 | 0.06 | 45 |
| CD14 | 1.1 | -1.1 | -1.4 | -1.9 | -2.5 | -3.4 | 0.01 | 10050 |
Differential expression (fold = infected/non-infected) with a FDR less than 0.05 at one or more time points and the averaged expression level (Exp) of genes in MHC antigen processing and presentation between infected and non-infected macrophages at 3, 6, 9, 12, 15 and 18 hours post infection.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr | FDR | Exp |
|---|---|---|---|---|---|---|---|---|
| SLA-DMB | -1.0 | 1.0 | -1.1 | -1.7 | -2.7 | -4.3 | 0.00 | 10386 |
| SLA-DMA | -1.0 | 1.0 | 1.1 | -1.0 | -1.4 | -2.1 | 0.02 | 4165 |
| SLA-DOA | 1.2 | 1.4 | 1.1 | 1.2 | 1.5 | 1.9 | 0.00 | 936 |
| SLA-DOB | 1.1 | 1.2 | 1.3 | 1.5 | 1.7 | 1.9 | 0.01 | 93 |
| CD74 / CLIP | 1.0 | 1.2 | 1.2 | 1.4 | 1.4 | 1.2 | 0.00 | 3546 |
| CTSA | -1.1 | -1.1 | 1.0 | -1.1 | -1.3 | -1.9 | 0.11 | 34618 |
| CTSB | -1.1 | -1.2 | -1.0 | -1.2 | -2.0 | -3.8 | 0.04 | 46406 |
| CTSC | -1.2 | -1.3 | -1.2 | -1.4 | -1.4 | -1.5 | 0.02 | 1757 |
| CTSH | -1.1 | -1.1 | 1.1 | -1.0 | -1.7 | -2.6 | 0.04 | 44195 |
| CTSL | -1.1 | -1.1 | -1.1 | -1.4 | -2.1 | -4.8 | 0.02 | 22078 |
| CTSS | 1.1 | 1.0 | -1.2 | -1.3 | -2.4 | -5.8 | 0.03 | 36684 |
| CTSV | 1.1 | -1.0 | -1.1 | -1.2 | -1.7 | -2.9 | 0.02 | 6988 |
| CALR | 1.1 | 1.0 | -1.1 | -1.3 | -1.5 | -2.3 | 0.02 | 24056 |
| PSMA1 | 1.0 | 1.1 | 1.0 | -1.1 | -1.4 | -1.6 | 0.05 | 2436 |
| PSMB1 | -1.2 | -1.2 | -1.0 | -1.2 | -1.6 | -1.9 | 0.02 | 18615 |
| PSMB10 | 1.1 | 1.2 | -1.1 | -1.3 | -1.4 | -2.0 | 0.02 | 14974 |
| PSMC1 | -1.1 | 1.0 | -1.0 | -1.1 | -1.3 | -1.7 | 0.01 | 3144 |
| PSMC3 | -1.1 | -1.1 | -1.1 | -1.2 | -1.3 | -1.7 | 0.02 | 14239 |
| PSMC6 | -1.2 | -1.2 | -1.1 | -1.1 | -1.2 | -1.7 | 0.03 | 1433 |
| PSMD1 | -1.0 | -1.3 | -1.5 | -1.5 | -1.9 | -2.3 | 0.00 | 4907 |
| PSMD11 | 1.0 | -1.1 | -1.1 | -1.1 | -1.4 | -1.5 | 0.02 | 915 |
| PSMD12 | -1.0 | -1.1 | -1.3 | -1.4 | -1.5 | -1.6 | 0.01 | 449 |
| PSMD2 | 1.1 | 1.0 | -1.3 | -1.3 | -1.6 | -2.0 | 0.01 | 10928 |
| PSMD5 | -1.1 | -1.2 | -1.1 | -1.1 | -1.3 | -1.6 | 0.01 | 411 |
| PSMD7 | -1.2 | -1.1 | -1.1 | -1.8 | -1.9 | -2.0 | 0.01 | 1101 |
| SEL1L | -1.2 | -1.3 | -1.2 | -1.3 | -2.1 | -2.7 | 0.00 | 621 |
Differential expression (fold = infected/non-infected) with a FDR less than 0.05 at one or more time points and the averaged expression level (Exp) of autophagy and apoptosis regulating genes between infected and non-infected macrophages at 3, 6, 9, 12, 15 and 18 hours post infection.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr | FDR | Exp |
|---|---|---|---|---|---|---|---|---|
| ATG2A | -1.0 | -1.2 | -1.2 | -1.2 | -1.5 | -2.0 | 0.01 | 3586 |
| ATG9A | -1.2 | -1.4 | -1.2 | -1.4 | -1.8 | -2.2 | 0.00 | 1428 |
| ATG101 | -1.3 | -1.2 | 1.0 | -1.5 | -1.7 | -1.7 | 0.01 | 1535 |
| ATG4B | -1.2 | -1.3 | -1.2 | -1.5 | -1.5 | -1.7 | 0.01 | 1044 |
| ATG7 | 1.1 | -1.1 | -1.1 | -1.1 | -1.3 | -1.6 | 0.01 | 288 |
| NUPR1 | 2.0 | 4.3 | 8.3 | 10.8 | 7.3 | 4.3 | 0.00 | 6096 |
| BNIP3 | -1.1 | -1.2 | -1.4 | -1.7 | -1.7 | -2.2 | 0.01 | 13384 |
| GADD45A | -1.6 | -1.6 | -1.1 | -3.5 | -5.5 | -6.8 | 0.00 | 804 |
Differential expression (fold = infected/non-infected) with a FDR less than 0.05 at one or more time points and the averaged expression level (Exp) of immune-related transcription factor, signal transducer and signaling inhibitor genes between infected and non-infected macrophages at 3, 6, 9, 12, 15 and 18 hours post infection.
| Gene | 3hr | 6hr | 9hr | 12hr | 15hr | 18hr | FDR | Exp |
|---|---|---|---|---|---|---|---|---|
| CEBPA | -1.2 | -1.1 | -1.1 | -2.4 | -3.3 | -4.0 | 0.00 | 12165 |
| CEBPB | -1.4 | -1.2 | -1.2 | -2.7 | -2.9 | -3.4 | 0.01 | 3548 |
| CEBPD | -1.5 | -2.2 | -1.3 | -4.1 | -6.5 | -9.9 | 0.00 | 5493 |
| CEBPE | -1.3 | -1.2 | -1.2 | -1.9 | -2.0 | -1.8 | 0.01 | 302 |
| CEBPG | -1.2 | -1.3 | -1.2 | -1.5 | -1.5 | -1.5 | 0.00 | 258 |
| CEBPZ | -1.2 | -1.0 | -1.0 | -1.4 | -1.7 | -1.7 | 0.01 | 1504 |
| CITED4 | -1.3 | -1.5 | 1.1 | -1.8 | -2.1 | -2.4 | 0.01 | 4977 |
| FOS | -1.2 | -1.1 | -1.1 | -2.8 | -2.2 | -2.9 | 0.04 | 235 |
| JUN | -1.5 | -1.7 | 1.0 | -1.9 | -2.4 | -2.7 | 0.00 | 734 |
| JUND | -1.2 | -1.2 | -1.2 | -1.7 | -1.8 | -1.8 | 0.01 | 2219 |
| IRF1 | 1.0 | 1.0 | -1.3 | -1.8 | -1.6 | -1.5 | 0.01 | 1177 |
| IRF5 | 1.0 | 1.2 | 1.3 | -1.1 | -1.4 | -1.8 | 0.02 | 3662 |
| FADD | -1.2 | 1.1 | 1.0 | -1.5 | -1.6 | -1.6 | 0.01 | 175 |
| MAP3K3 | -1.2 | -1.4 | -1.0 | -1.4 | -1.7 | -1.8 | 0.01 | 522 |
| MAP3K5 | 1.0 | -1.4 | -1.4 | -1.4 | -1.4 | -1.4 | 0.02 | 318 |
| MAP4K3 | -1.2 | -1.2 | -1.1 | -1.4 | -1.6 | -1.8 | 0.00 | 251 |
| MAPK7 | -1.2 | -1.2 | -1.1 | -1.2 | -1.3 | -1.5 | 0.01 | 1607 |
| TAB1 | -1.2 | -1.4 | -1.3 | -1.5 | -1.7 | -2.1 | 0.00 | 1577 |
| TBK1 | -1.2 | -1.2 | -1.1 | -1.7 | -2.0 | -2.0 | 0.00 | 897 |
| TRADD | -1.1 | -1.3 | -1.3 | -1.6 | -2.0 | -2.4 | 0.00 | 3866 |
| SIGLEC1 | 1.8 | 5.4 | 6.5 | 6.6 | 6.6 | 4.7 | 0.01 | 1472 |
| SOCS1 | 1.7 | 3.2 | 2.0 | 1.3 | 1.5 | 1.4 | 0.02 | 1149 |
| USP18 | 1.9 | 5.2 | 5.2 | 5.5 | 4.3 | 3.5 | 0.00 | 5418 |
Hypothesized mechanisms of African swine fever virus pathogenesis and immune evasion inferred from differentially expressed genes (DEG) down- or up-regulated in infected macrophages with listed references used for biological inferences and tables contain the DEG.
| Mechanisms | DEG | Expression | Table | Biological activity | Reference |
|---|---|---|---|---|---|
| Hemorrhagic fever by cytokine storm | TNFs, IFNs, IL17 | up | Pro-inflammation | ||
| IL10 | down | anti-inflammation | |||
| Neutrophilia / inhibition of NETs | CSF3 | up | neutrophil production | ||
| ELR+ CXCLs | down | neutrophil recruitment | |||
| Lymphopenia / T cell suppression | TNFSF10 | up | lymphocyte toxicity | ||
| CXCL10, CXCL16 | up | T cell recruitment | |||
| IL27, IDO1 | up | Treg cell differentiation | |||
| Suppression of macrophage M1 activation | P2Rs, TLRs | down | macrophage M1 activation | ||
| C3AR1, C5AR1 | down | macrophage M1 activation | |||
| IL13 | up | macrophage M2 activation | |||
| IFN & TNF receptors | down | macrophage M1 activation | |||
| Cytokine signaling inhibition | SIGLEC1, USP18, SOCS1 | up | cytokine signaling suppression | ||
| TRADD, FADD | down | TNF signal transduction | |||
| IL1RN, IL18BP | up | IL1 & IL18 signaling inhibition | |||
| 12 TFs, 8 STs | down | cytokine signal transduction | |||
| Inhibition of MHC epitope processing, loading and presentation | SLA-DMA, SLA-DMB | down | MHC Class II epitope loading | ||
| SLA-DOA, SLA-DOB | up | inhibition of SLA-DM | |||
| CTSs & PSMs | down | MHC epitope procession | |||
| 5 ATGs | down | endogenous antigen routing | |||
| IL7R, NUPR1 | up | autophagy inhibition | |||
| GADD45, BNIP3 | down | autophagy and apoptosis | |||
| TNFSF11, TNFSF15 | down | MHC antigen presentation | |||
| Inhibition of classical monocyte recruitment | CCL2 | Down | classical monocytes | ||
| CCL3, CCL4, CCL5 | up | non-classical monocytes |
1 NETs: neutrophil extracellular traps
2 TFs: immune-related transcription factor and STs: signal transducers